Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Benzenesulfonic acid, para-, monoalkylation products with C14-C18 branched olefins (C15 rich) derived from propene oligomerization, calcium salt, overbased including distillates (petroleum), hydrotreated, solvent-refined, solvent-dewaxed, or catalytic dewaxed, light or heavy paraffinic C15-C50
EC number: 701-205-4 | CAS number: -
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEC
- 49.5 mg/m³
- Study duration:
- subacute
- Species:
- rat
Additional information
Multiple repeat dose studies on representative alkaryl sulfonate salts are available to assess the hazard following repeated exposure of EC No. 271 -877 -7.
Oral repeated dose: The ACC study on CAS # 115733 -09 -0 is selected as the key study to meet the endpoint requirement for the registration because it is most chemically similar to the substance being registered. In a fully compliant OECD 407 Guideline study, a NOAEL of 1000 mg/kg bw/day was established in male and female rat.
Dermal repeated dose: No study is available for this endpoint. However, according to the Commission Guidance on Dermal Absorption, 2004, absorption is expected to be limited for substances with molecular weight > 500 and Log Kow values outside the range of 1 - 2. Based on this guidance, alkaryl sulfonate salts would generally be expected to be very poorly absorbed in contact with skin. Because of this and because data are available for the oral and inhalation routes of exposure following repeat dosing, it is considered unnecessary to generate data by this route of exposure. This endpoint is waived.
Inhalation repeated dose: A single valid study on a representative alkaryl sulfonate salt is available to evalute the toxicity of the substance following repeated inhalation exposure. The data are considered adequate for this purpose. A NOAEL of 49.5 mg/m3 was established in this study.
Justification for classification or non-classification
Representative alkylbenzene sulfonate salts do not meet the criteria set out in Directive 67/548/EEC and also Regulation (EC) 1272/2008 for target organ effects following repeated exposure. Classification of EC No. 271 -877 -7 for effects following repeated exposure is not considered to be necessary based on chemical similarity to those representative substances.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
